NasdaqGS:ANIKBiotechs
Anika Therapeutics Q4 Profit Challenges Narratives Around Ongoing Losses For ANIK Investors
Anika Therapeutics (ANIK) closed out FY 2025 with Q4 revenue of US$30.6 million and basic EPS of US$0.13, alongside net income excluding extra items of US$1.8 million, providing a cleaner snapshot of its ongoing operations. Over recent quarters, the company reported revenue of US$26.2 million in Q1 2025, US$28.2 million in Q2, US$27.8 million in Q3, and US$30.6 million in Q4. EPS ranged from a loss of US$0.32 in Q2 to a profit of US$0.13 in Q4, giving investors a clearer view of how margins...